Whole-genome CRISPR-Cas9 screens are a powerful tool for identifying key genes or biomarkers mediating drug resistance.9–11 A better understanding of these genes will help develop novel combination therapies.12 Several PD-L1 regulators, including CMTM6 and CMTM4, have been identified via CRISPR screens, which potently facilitate combination immunotherapies for cancer;13–15 however, such screening approach has not been utilized in G.C. MAGeCK is a comprehensive workflow that can be used for CRISPR screening data analyses.16,17. Here, CD274 is linked to cancer.